Cargando…
A New Source of Heterogeneity in Comparative and Translational Clinical Trials: The “Border-Time” Bias
SIMPLE SUMMARY: Target-oriented drugs are profoundly changing the anti-cancer treatments. Progression-free survival is a primary or co-primary endpoint in the large part of comparative and translational clinical trials about target-oriented anti-cancer agents. In this context, the time before treatm...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
MDPI
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9654809/ https://www.ncbi.nlm.nih.gov/pubmed/36358684 http://dx.doi.org/10.3390/cancers14215265 |